A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.

Shubham Pant,Michel Ducreux,James J. Harding,Milind Javle,Do-Youn Oh,Harpreet Wasan,Allison Fortenberry,Neil C. Josephson,Anthony Mwatha,Kui Wang,Jia Fan

A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.

2021

Shubham Pant
Michel Ducreux
James J. Harding
Milind Javle
Do-Youn Oh
Harpreet Wasan
Allison Fortenberry
Neil C. Josephson
Anthony Mwatha
Kui Wang
Jia Fan

TPS352Background: Advanced biliary tract cancers (BTCs), including gallbladder cancer (GBC) and cholangiocarcinoma (CC), have a poor prognosis. Zanidatamab (ZW25) is a novel bispecific antibody tha...

Keywords:

Single Arm Study
Internal medicine
Biliary tract
Medicine
open label
Gastroenterology
poor prognosis
Gallbladder cancer
bispecific antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations